MX2016005801A - Terapia de combinacion de un anticuerpo anti cd20 con un inhibidor de btk. - Google Patents

Terapia de combinacion de un anticuerpo anti cd20 con un inhibidor de btk.

Info

Publication number
MX2016005801A
MX2016005801A MX2016005801A MX2016005801A MX2016005801A MX 2016005801 A MX2016005801 A MX 2016005801A MX 2016005801 A MX2016005801 A MX 2016005801A MX 2016005801 A MX2016005801 A MX 2016005801A MX 2016005801 A MX2016005801 A MX 2016005801A
Authority
MX
Mexico
Prior art keywords
antibody
combination therapy
btk inhibitor
cancer
directed
Prior art date
Application number
MX2016005801A
Other languages
English (en)
Inventor
Klein Christian
Toshio Yoshizawa
Tomoko Yasuhiro
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of MX2016005801A publication Critical patent/MX2016005801A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a la terapia de combinación de un anticuerpo anti-CD20 con un inhibidor de BTK para el tratamiento del cáncer, especialmente a la terapia de combinación de cánceres que expresan CD20 con un anticuerpo anti-CD20 de tipo I o un anticuerpo B-Ly1 humanizado afucosilado y un inhibidor de BTK.
MX2016005801A 2013-11-07 2014-11-04 Terapia de combinacion de un anticuerpo anti cd20 con un inhibidor de btk. MX2016005801A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13192006 2013-11-07
PCT/EP2014/073640 WO2015067586A2 (en) 2013-11-07 2014-11-04 Combination therapy of an anti cd20 antibody with a btk inhibitor

Publications (1)

Publication Number Publication Date
MX2016005801A true MX2016005801A (es) 2016-11-29

Family

ID=49552219

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016005801A MX2016005801A (es) 2013-11-07 2014-11-04 Terapia de combinacion de un anticuerpo anti cd20 con un inhibidor de btk.

Country Status (21)

Country Link
US (2) US20150125446A1 (es)
EP (1) EP3066126B1 (es)
JP (1) JP6478989B2 (es)
KR (1) KR101874215B1 (es)
CN (3) CN113995843A (es)
AR (1) AR098328A1 (es)
AU (1) AU2014345712B2 (es)
BR (1) BR112016010271A2 (es)
CA (1) CA2926893C (es)
ES (1) ES2728350T3 (es)
HK (1) HK1222803A1 (es)
IL (1) IL244960B (es)
MX (1) MX2016005801A (es)
MY (1) MY178726A (es)
NZ (1) NZ718792A (es)
PH (1) PH12016500839A1 (es)
PL (1) PL3066126T3 (es)
RU (1) RU2727650C2 (es)
TR (1) TR201907240T4 (es)
TW (1) TWI524899B (es)
WO (1) WO2015067586A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106046159B (zh) 2010-03-12 2020-06-16 德彪发姆国际有限公司 Cd37结合分子及其免疫缀合物
MY189483A (en) 2010-05-31 2022-02-16 Ono Pharmaceutical Co Purinone derivative
PL2786996T3 (pl) 2011-11-29 2017-01-31 Ono Pharmaceutical Co., Ltd. Chlorowodorowa pochodna purynonu
JP6528779B2 (ja) * 2014-03-25 2019-06-12 小野薬品工業株式会社 びまん性大細胞型ｂ細胞リンパ腫の予防および／または治療剤
WO2016049214A1 (en) * 2014-09-23 2016-03-31 Genentech, Inc. METHOD OF USING ANTI-CD79b IMMUNOCONJUGATES
ES2955554T3 (es) 2015-04-09 2023-12-04 Ono Pharmaceutical Co Proceso para producir un derivado de purinona
JP6979877B2 (ja) 2015-06-08 2021-12-15 デビオファーム インターナショナル， エス． アー． 抗ｃｄ３７イムノコンジュゲートおよび抗ｃｄ２０抗体の組み合わせ
CA2985718A1 (en) 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Anti-transferrin receptor antibodies with tailored affinity
EA201890347A1 (ru) 2015-08-28 2018-09-28 Дебиофарм Интернэшнл, С.А. Антитела и исследования для обнаружения cd37
JP2018530550A (ja) * 2015-10-01 2018-10-18 ギリアド サイエンシズ， インコーポレイテッド 癌を治療するためのｂｔｋ阻害剤とチェックポイント阻害剤との組合せ
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
EP3355871A1 (en) * 2015-10-02 2018-08-08 Gilead Sciences, Inc. Combinations of the btk inhibitor gs-4059 with inhibitors selected from a jak, ask1, brd and/or mmp9 inhibitor to treat cancer, allergic disorders, autoimmune diseases or inflammatory diseases
PE20231655A1 (es) 2015-10-02 2023-10-17 Hoffmann La Roche Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso
EP3535297B1 (en) 2016-11-02 2022-08-10 Debiopharm International, S.A. Methods for improving anti-cd37 immunoconjugate therapy
US20180206726A1 (en) 2016-12-07 2018-07-26 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
US20210138213A1 (en) 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
EP3658584A1 (en) * 2017-07-26 2020-06-03 H. Hoffnabb-La Roche Ag Combination therapy with a bet inhibitor, a bcl-2 inhibitor and an anti-cd20 antibody
KR20200035441A (ko) 2017-08-08 2020-04-03 에프. 호프만-라 로슈 아게 Dlbcl 환자 하위그룹의 오비누투주맙 치료
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US20230009902A1 (en) 2018-06-20 2023-01-12 Progenity, Inc. Treatment of a disease or condition in a tissue orginating from the endoderm
EP3883635A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
CN115666704A (zh) 2019-12-13 2023-01-31 比奥拉治疗股份有限公司 用于将治疗剂递送至胃肠道的可摄取装置

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1034298B1 (en) * 1997-12-05 2011-11-02 The Scripps Research Institute Humanization of murine antibody
CN101928344B (zh) * 2002-10-17 2014-08-13 根马布股份公司 抗cd20的人单克隆抗体
EP2178916B1 (en) * 2007-07-31 2014-12-17 Regeneron Pharmaceuticals, Inc. Human antibodies to human cd20 and method of using thereof
MY189483A (en) * 2010-05-31 2022-02-16 Ono Pharmaceutical Co Purinone derivative
KR102054468B1 (ko) * 2011-10-19 2019-12-11 파마싸이클릭스 엘엘씨 브루톤 티로신 인산화효소(btk)의 억제제의 용도
US20130302274A1 (en) * 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
PL2786996T3 (pl) * 2011-11-29 2017-01-31 Ono Pharmaceutical Co., Ltd. Chlorowodorowa pochodna purynonu
TW201427667A (zh) * 2012-11-20 2014-07-16 Celgene Avilomics Res Inc 治療和布魯頓（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶相關之疾病或失調的方法

Also Published As

Publication number Publication date
RU2727650C2 (ru) 2020-07-22
KR101874215B1 (ko) 2018-07-03
WO2015067586A3 (en) 2015-07-30
WO2015067586A2 (en) 2015-05-14
NZ718792A (en) 2020-05-29
MY178726A (en) 2020-10-20
US20150125446A1 (en) 2015-05-07
BR112016010271A2 (pt) 2017-10-03
CN105792846A (zh) 2016-07-20
CA2926893A1 (en) 2015-05-14
JP2016536298A (ja) 2016-11-24
IL244960A0 (en) 2016-05-31
ES2728350T3 (es) 2019-10-23
EP3066126A2 (en) 2016-09-14
RU2016122232A (ru) 2017-12-08
TR201907240T4 (tr) 2019-06-21
RU2016122232A3 (es) 2018-06-18
KR20160079869A (ko) 2016-07-06
PH12016500839A1 (en) 2016-06-13
CA2926893C (en) 2022-04-12
AU2014345712A1 (en) 2016-05-05
EP3066126B1 (en) 2019-03-27
US20200171153A1 (en) 2020-06-04
PL3066126T3 (pl) 2019-08-30
CN114632158A (zh) 2022-06-17
IL244960B (en) 2021-08-31
AU2014345712B2 (en) 2019-10-17
CN113995843A (zh) 2022-02-01
AR098328A1 (es) 2016-05-26
TWI524899B (zh) 2016-03-11
JP6478989B2 (ja) 2019-03-06
HK1222803A1 (zh) 2017-07-14
TW201521767A (zh) 2015-06-16

Similar Documents

Publication Publication Date Title
PH12016500839A1 (en) Combination theraphy of an anti cd20 antibody with a btk inhibitor
NZ736727A (en) Combination therapy of an anti cd20 antibody with a bcl-2 inhibitor and a mdm2 inhibitor
GEP20217331B (en) Anti-tigit antibodies
MX2013006739A (es) Terapia combinada de anticuerpo cd20 afucosilado con inhibidor de mdm2.
MX355849B (es) Terapia de combinacion de un anticuerpo cd20 afucosilado y bendamustina.
TN2015000396A1 (en) Antibody drug conjugates
EP4302835A3 (en) Methods of treating ovarian cancer
MY181960A (en) Combination therapy of an afucosylated cd20 antibody with a cd79b antibody-drug conjugate
MX2015002947A (es) Terapia de combinacion de un anticuerpo ant-cd20 tipo ii con un inhibidor blc-2 selectivo.
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
MX2019003780A (es) Uso de la combinación de anticuerpo anti-pd-1 e inhibidor de vegfr en la preparación de medicamentos para el tratamiento de cánceres.
MX2016002826A (es) Anticuerpos anti-b7-h1 para tratar tumores.
MX2016015181A (es) Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
MX2016002645A (es) Tratamiento combinado para tratar el glioblastoma.
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
NZ711867A (en) Combination therapy of an afucosylated cd20 antibody with a cd22 antibody-drug conjugate
MX2012012118A (es) Terapia de combinacion de un anticuerpo cd20 afucosilado con un inhibidor mtor.
PH12014501543A1 (en) Combination therapy for the treatment of ovarian cancer
MX2012001783A (es) Terapia combinatoria de un anticuerpo anti-cd20 afucosilado con fludarabina y/o mitoxantrona.
EA201591304A1 (ru) Применение комплекса, облегчающего транскрипцию хроматина (fact), при раке

Legal Events

Date Code Title Description
FG Grant or registration